| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypersensitivity | D006967 | 22 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Urination Disorders | D014555 | 9 associated lipids |
| Arterial Occlusive Diseases | D001157 | 12 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Leukemia, Erythroblastic, Acute | D004915 | 41 associated lipids |
| Vision Disorders | D014786 | 10 associated lipids |
| Multiple Myeloma | D009101 | 13 associated lipids |
| Osteochondrodysplasias | D010009 | 3 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Hematologic Diseases | D006402 | 3 associated lipids |
| Muscular Dystrophies | D009136 | 10 associated lipids |
| Osteoporosis | D010024 | 12 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
| Kidney Diseases | D007674 | 29 associated lipids |
| Hematuria | D006417 | 13 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Grenier FC et al. | A whole blood FK 506 assay for the IMx analyzer. | 1991 | Transplant. Proc. | pmid:1721264 |
| Friob MC et al. | A combined HPLC-ELISA evaluation of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721265 |
| Machida M et al. | Effect of temperature and hematocrit on plasma concentration of FK 506. | 1991 | Transplant. Proc. | pmid:1721266 |
| Kawauchi M et al. | Plasma level of FK 506 in newborn goats and infant baboons. | 1991 | Transplant. Proc. | pmid:1721267 |
| Iwasaki K et al. | Pharmacokinetic study of FK 506 in the rat. | 1991 | Transplant. Proc. | pmid:1721268 |
| Kay JE et al. | Uptake of FK 506 by lymphocytes and erythrocytes. | 1991 | Transplant. Proc. | pmid:1721269 |
| Jain AB et al. | Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721270 |
| Abu-Elmagd KM et al. | Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1721271 |
| Bierer BE et al. | FK 506 and rapamycin: molecular probes of T-lymphocyte activation. | 1991 | Transplant. Proc. | pmid:1721296 |
| Tanida I et al. | Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. | 1991 | Transplant. Proc. | pmid:1721297 |
| O'Neill EA et al. | The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. | 1991 | Transplant. Proc. | pmid:1721298 |
| Nelson PA et al. | Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. | 1991 | Transplant. Proc. | pmid:1721299 |
| Dumont FJ et al. | Up-regulation of gene expression by FK 506. | 1991 | Transplant. Proc. | pmid:1721300 |
| Rao P et al. | Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. | 1991 | Transplant. Proc. | pmid:1721301 |
| DiLella AG and Craig RJ | Characterization of the human FKBP-12 gene and related pseudogenes. | 1991 | Transplant. Proc. | pmid:1721302 |
| Kar S and Carr B | Gene expression of FK 506-binding protein. | 1991 | Transplant. Proc. | pmid:1721303 |
| Didlake R and Grogan J | Effect of FK 506 on rat leukocyte chemotaxis. | 1991 | Transplant. Proc. | pmid:1721327 |
| Hultsch T and Hohman RJ | Categorizing receptor-signaling pathways with FK 506 and rapamycin. | 1991 | Transplant. Proc. | pmid:1721328 |
| Takai K et al. | Immunosuppressive effects of FK 506 on rat lymphoid organs. | 1991 | Transplant. Proc. | pmid:1721329 |
| Ishibashi M et al. | Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. | 1991 | Transplant. Proc. | pmid:1721330 |
| Kawauchi M et al. | Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. | 1991 | Transplant. Proc. | pmid:1721331 |
| Borg AJ and Kumagai M | FK 506 and xenogeneic human anti-porcine cellular reactivity. | 1991 | Transplant. Proc. | pmid:1721332 |
| Fung J et al. | A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. | 1991 | Transplant. Proc. | pmid:1721333 |
| Winkler M et al. | Use of FK 506 for treatment of chronic rejection after liver transplantation. | 1991 | Transplant. Proc. | pmid:1721334 |
| D'Alessandro AM et al. | FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1721335 |
| Lewis WD et al. | FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. | 1991 | Transplant. Proc. | pmid:1721336 |
| Schreiber SL | Chemistry and biology of the immunophilins and their immunosuppressive ligands. | 1991 | Science | pmid:1702904 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Dew MA et al. | Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721360 |
| Shapiro R et al. | FK 506 in clinical kidney transplantation. | 1991 | Transplant. Proc. | pmid:1721361 |
| McCauley J et al. | Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. | 1991 | Transplant. Proc. | pmid:1721362 |
| Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721363 | |
| Jensen CW et al. | Pediatric renal transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721364 |
| Jordan ML et al. | FK 506 conversion of renal allografts failing cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721365 |
| Offner G et al. | FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. | 1991 | Transplant. Proc. | pmid:1721366 |
| Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721367 | |
| Demetris AJ et al. | Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703360 |
| Thomson AW et al. | The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. | 1991 | Transplant. Proc. | pmid:1703361 |
| Mieles L et al. | Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1703362 |
| Warty V et al. | Distribution of FK 506 in plasma lipoproteins in transplant patients. | 1991 | Transplant. Proc. | pmid:1703363 |
| Kusne S et al. | Early infections in kidney transplant recipients under FK 506. | 1991 | Transplant. Proc. | pmid:1703364 |
| Rilo HL et al. | Effect of FK 506 on function of human islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1721393 |
| Carroll PB et al. | Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. | 1991 | Transplant. Proc. | pmid:1721394 |
| Scantlebury V et al. | New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. | 1991 | Transplant. Proc. | pmid:1721395 |
| Carroll PB et al. | FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. | 1991 | Transplant. Proc. | pmid:1721396 |
| Freise CE et al. | Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721397 |
| Eidelman BH et al. | Neurologic complications of FK 506. | 1991 | Transplant. Proc. | pmid:1721398 |
| Steinmann B et al. | Mechanism of action of FK 506 and cyclosporin. | 1991 | Lancet | pmid:1704088 |
| Santiago SF et al. | Effect of donor pretreatment with FK 506 upon small intestine allotransplantation in rats. | 1991 | Transplant. Proc. | pmid:1721423 |
| Murase N et al. | Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721424 |
| Langrehr JM et al. | Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. | 1991 | Transplant. Proc. | pmid:1721425 |
| Takeda Y et al. | Effect of FK 506 on the survival of rat small bowel allografts. | 1991 | Transplant. Proc. | pmid:1721426 |
| Fukuzawa M et al. | Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. | 1991 | Transplant. Proc. | pmid:1721427 |
| Ogasa N et al. | Effect of FK 506 on growth of transplanted newborn rat intestine. | 1991 | Transplant. Proc. | pmid:1721428 |
| de Bruin RW et al. | Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721429 |
| Langrehr JM et al. | FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. | 1991 | Transplant. Proc. | pmid:1721430 |
| Ringe D | Immunosuppression. Binding by design. | 1991 | Nature | pmid:1710317 |
| Tropschug M and Hofmann R | FK506 and protein kinase C. | 1991 | Nature | pmid:1710319 |
| Albers MW et al. | Relationship of FKBP to PKCI-2. | 1991 | Nature | pmid:1710782 |
| Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
| Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Neuberger J | FK 506--a promise of good things to come? | 1991 | Hepatology | pmid:1711005 |
| Halloran PF and Madrenas J | The mechanism of action of cyclosporine: a perspective for the 90's. | 1991 | Clin. Biochem. | pmid:1711939 |
| Liversidge J et al. | FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. | 1991 | Transplant. Proc. | pmid:1721455 |
| Mochizuki M et al. | A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. | 1991 | Transplant. Proc. | pmid:1721456 |
| Roat MI et al. | Treatment of Cogan's syndrome with FK 506: a case report. | 1991 | Transplant. Proc. | pmid:1721457 |
| Carroll PB et al. | The use of FK 506 in new-onset type I diabetes in man. | 1991 | Transplant. Proc. | pmid:1721458 |
| McCauley J et al. | FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. | 1991 | Transplant. Proc. | pmid:1721459 |
| Carrieri G et al. | Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. | 1991 | Transplant. Proc. | pmid:1721460 |
| Deguchi K et al. | Effects of FK 506 on acute experimental allergic encephalomyelitis. | 1991 | Transplant. Proc. | pmid:1721461 |
| Bolton C | The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. | 1991 | Transplant. Proc. | pmid:1721462 |
| Calne RY | Immunosuppression for organ grafting. | 1991 | Transplant. Proc. | pmid:1714646 |
| Starzl TE et al. | Notes on FK 506. | 1991 | Transplant. Proc. | pmid:1714647 |
| Haba T et al. | Pathological and immunohistochemical examination in the rat treated with FK 506. | 1991 | Transplant. Proc. | pmid:1714649 |
| Forrest MJ et al. | FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. | 1991 | Biochem. Pharmacol. | pmid:1716098 |
| Lautenschlager I et al. | Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. | 1991 | Transplant. Proc. | pmid:1714650 |
| DiLella AG and Craig RJ | Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. | 1991 | Biochemistry | pmid:1716149 |
| Epand RF and Epand RM | The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. | 1991 | Anticancer Drug Des. | pmid:1714737 |
| McKeon F | When worlds collide: immunosuppressants meet protein phosphatases. | 1991 | Cell | pmid:1716181 |
| Christians U et al. | Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. | 1991 | Clin. Biochem. | pmid:1714802 |
| Petros AM et al. | NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. | 1991 | J. Med. Chem. | pmid:1716684 |
| Turka LA and Thompson CB | Structure-function relationship of immunosuppressive drugs: a cautionary tale. | 1991 | Hepatology | pmid:1714876 |
| FK 506--an investigational immunosuppressant. | 1991 | Med Lett Drugs Ther | pmid:1716722 | |
| Brizuela L et al. | Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. | 1991 | Mol. Cell. Biol. | pmid:1715022 |
| Heitman J et al. | Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. | 1991 | Science | pmid:1715094 |
| Sakr MF et al. | Protective effect of FK 506 against hepatic ischemia in rats. | 1991 | Transplant. Proc. | pmid:1703689 |
| Katayama Y et al. | Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1703690 |
| Thomson AW | The immunosuppressive macrolides FK-506 and rapamycin. | 1991 | Immunol. Lett. | pmid:1717376 |
| Takaya S et al. | Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1703691 |
| Steeves M et al. | In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. | 1991 | J. Pharm. Pharmacol. | pmid:1717676 |
| Hildebrandt A et al. | FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1703694 |
| Unmasking immunosuppression. | 1991 | Lancet | pmid:1717800 | |
| Ericzon BG et al. | Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. | 1991 | Transplant. Proc. | pmid:1703695 |
| Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
| Kumano K et al. | FK 506-induced nephrotoxicity in rats. | 1991 | Transplant. Proc. | pmid:1703696 |
| Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
| Kuroki H et al. | Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1703697 |
| Starzl TE et al. | Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. | 1991 | Transplantation | pmid:1718068 |
| Morris RE et al. | Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. | 1991 | Transplant. Proc. | pmid:1703698 |